Who Paid My Doc
Phase 2 Episodic Migraine Prophylaxis EMP
Research payments
$894,012
Through program year 2024, $894,012 in research payments was reported against Phase 2 Episodic Migraine Prophylaxis EMP, across 265 payments, paid by Amgen Inc..
- Paid by
- Amgen Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $16,135 | 1 |
| 2021 | Research | $7,939 | 5 |
| 2020 | Research | $152,567 | 67 |
| 2019 | Research | $717,372 | 192 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Christopher O Carroll Newport Beach, CA Named on 16 payments
- David Kudrow Santa Moncia, CA Named on 11 payments
- Stephen Silberstein Philadelphia, PA Named on 10 payments
- Matthew Davis Rochester, NY Named on 9 payments
- Joel Saper Ann Arbor, MI Named on 9 payments
- Paul Winner West Palm Beach, FL Named on 9 payments
- Jan Brandes Nashville, TN Named on 9 payments
- Martin Schuster Sherman Oaks, CA Named on 9 payments
- Dario Zagar Fairfield, CT Named on 8 payments
- Jo Bonner St. Louis, MO Named on 8 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.